DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Phase 2

Active, not recruiting

Conditions: Netherton Syndrome

Interventions: Drug: Spesolimab - solution for infusion
Drug: Placebo matching to spesolimab - solution for infusion
Drug: Spesolimab - solution for injection
Drug: Placebo matching to spesolimab - solution for injection

First Posted Date: 2023-05-12

Last Posted Date: 2025-04-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT05856526

Locations: 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 24 locations

Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

Active, not recruiting

Conditions: Arthritis, Rheumatoid
Lung Diseases, Interstitial

First Posted Date: 2023-05-11

Last Posted Date: 2025-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1203

Registration Number: NCT05855109

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital General Universitario De Valencia, Valencia, Spain
🇪🇸
Hospital Do Meixoeiro, Vigo, Spain

and more 25 locations

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Phase 2

Active, not recruiting

Conditions: Bronchiectasis

Interventions: Drug: BI 1291583
Drug: Placebo matching BI 1291583

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 269

Registration Number: NCT05846230

Locations: 🇧🇬
Medical Center "Zdrave-1", Kozloduy, Bulgaria
🇧🇬
Medica Center Hera - Montana Branch, Montana, Bulgaria
🇧🇬
Medical Center ReSpiro Ltd, Razgrad, Bulgaria

and more 99 locations

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: BI 1821736

First Posted Date: 2023-05-03

Last Posted Date: 2025-04-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT05839600

Locations: 🇸🇪
Karolinska Universitetssjukhuset Stockholm, Stockholm, Sweden
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
NEXT Oncology-San Antonio-65273, San Antonio, Texas, United States

and more 4 locations

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583 mixed with [C-14] BI 1291583

First Posted Date: 2023-04-27

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT05833035

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631
Drug: Itraconazole

First Posted Date: 2023-04-27

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT05833139

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Not yet recruiting

Conditions: Lung Diseases, Interstitial

First Posted Date: 2023-04-19

Last Posted Date: 2025-04-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 312

Registration Number: NCT05819385

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 1
Drug: Spesolimab Formulation 2
Drug: Placebo matching Spesolimab Formulation 2

First Posted Date: 2023-04-19

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 209

Registration Number: NCT05819398

Locations: 🇯🇵
Dokkyo Medical University Hospital, Tochigi, Shimotsuga-gun, Japan
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States

and more 155 locations

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Pirfenidone

First Posted Date: 2023-03-22

Last Posted Date: 2023-09-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2778

Registration Number: NCT05779007

Locations: 🇺🇸
Boehringer Ingelheim, Ridgefield, Connecticut, United States

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Phase 1

Completed

Conditions: Healthy
Obesity

Interventions: Drug: Placebo
Drug: BI 1820237
Drug: BI 456906
Drug: semaglutide

First Posted Date: 2023-03-02

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 88

Registration Number: NCT05751226

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy